Ocugen Earnings Call Transcripts
Fiscal Year 2026
-
Phase II results for OCU410 in GA showed a 31% reduction in lesion growth at 12 months with a favorable safety profile and significant preservation of photoreceptor structure. The medium dose will advance to phase III, targeting a global enrollment of 300 patients.
-
OCU410, a one-time gene therapy for geographic atrophy, showed a 46% reduction in lesion growth at 12 months in phase II, with a strong safety profile and up to 50% of patients achieving significant benefit. The therapy targets multiple disease pathways and may offer a durable alternative to chronic injections.
Fiscal Year 2025
-
Significant clinical and operational progress was made across gene therapy programs, with key trials advancing and positive data reported. Financial position was strengthened through fundraising and licensing, supporting a cash runway into late 2026 or beyond.
-
OCU400 and OCU410ST gene therapy programs advanced toward late-stage regulatory milestones, with strong clinical progress, expanded global partnerships, and a strengthened cash position supporting operations into 2026. Manufacturing and commercialization plans are on track for 2027 launches.
-
Three gene therapy programs for major blindness diseases are advancing toward BLA filings between 2026 and 2028, with OCU400 leading in Phase 3 for retinitis pigmentosa. Early clinical data show strong safety and efficacy, and recent financial moves have extended the cash runway into 2027.
-
Advanced late-stage gene therapy programs for RP, Stargardt, and GA, with key regulatory and clinical milestones achieved. Cash position declined to $27.3M, with ongoing strategic partnerships and non-dilutive funding efforts. Top-line data and regulatory filings expected in 2026-2027.
-
Advanced gene therapy programs achieved key regulatory milestones, with pivotal trials and BLA/MAA filings on track over the next three years. R&D expenses rose, net loss widened, and cash runway extends into Q1 2026. EMA and FDA support underscores strong market potential.
Fiscal Year 2024
-
Advanced three gene therapy programs with positive clinical data and regulatory progress, secured $65M in new financing, and extended cash runway into Q1 2026. BLA filings targeted for 2026–2028, with pivotal trials and interim data expected in 2025.
-
Modifier gene therapy programs for retinal diseases are advancing, with OCU400, OCU410, and OCU410-ST showing strong safety, efficacy, and patient-reported benefits. Market opportunities are significant, and the one-time treatment approach aims to address major unmet needs while ensuring global access.
-
Achieved major clinical and regulatory milestones, including approvals for OCU400 and OCU200 trials, and secured $30 million in debt financing to extend cash runway into Q1 2026. Operating expenses declined year-over-year, and multiple gene therapy programs advanced with key data updates expected soon.
-
The company is advancing a novel modified gene therapy platform for retinal diseases, with OCU400 in phase III for RP and LCA, and OCU410/OCU410ST in trials for geographic atrophy and Stargardt disease. Early data show broad efficacy and safety, with regulatory submissions targeted for 2026.
-
The gene therapy platform is advancing with OCU400 in phase III for RP and OCU410 in phase I/II for dry AMD and Stargardt disease, targeting broad patient populations. Regulatory progress and expanded access programs support global reach, with key data and partnership milestones expected by year-end.
-
Advanced gene therapy programs progressed, highlighted by OCU400's expanded access approval and strong regulatory momentum. Operating expenses fell 31% year-over-year, and a $32.6M fundraising extends cash runway into Q3 2025.